Trial Profile

SQUINT (Squamous Immunotherapy Nivolumab-Ipilimumab Trial): An Open-label, Randomized, Parallel, Non Comparative, Phase II Trial of Nivolumab Plus Ipilimumab Versus Platinum-based Chemotherapy Plus Nivolumab in Chemonaive Metastatic or Recurrent Squamous-Cell Lung Cancer (SqLC)

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 27 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel
Indications Lung cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms SQUINT

13 Sep 2022 Results of an analysis assessing the molecular predictors of immunotherapy efficacy in lung squamous-cell carcinoma presented at the 47th European Society for Medical Oncology Congress
09 Aug 2022 preliminary results (n=91) presented at the 2022 World Conference on Lung Cancer
10 Sep 2019 Trial design presented at the 20th World Conference on Lung Cancer.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com